Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Bayley

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The New Zealand Medical Journal|August 31, 2012
Foot problems in Maori with diabetesBelinda Ihaka, Angela Bayley, Keith Rome
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2015
Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host DiseaseKenneth F Bradstock, Ian Bilmon, John Kwan, et al.
Leukemia & Lymphoma|September 13, 2019
Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantationMaansi Joshi, John Taper, Cecily Forsyth, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The New Zealand Medical Journal|August 31, 2012
Foot problems in Maori with diabetesBelinda Ihaka, Angela Bayley, Keith Rome
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2015
Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host DiseaseKenneth F Bradstock, Ian Bilmon, John Kwan, et al.
Leukemia & Lymphoma|September 13, 2019
Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantationMaansi Joshi, John Taper, Cecily Forsyth, et al.
Pageof 1